Oslo, Norway, 6 October 2021 - Targovax ASA (OSE: TRVX), a clinical stage immuno
-oncology company developing immune activators to target hard-to-treat solid
tumors, today announces that two abstracts has been accepted for poster
presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.

The abstracts will be released on the SITC website 9 November 14:00 CEST
(www.sitcancer.org/2021/home). The posters are scheduled for presentation during
the SITC congress 12-14 November 2021.

Poster    A randomised open-label phase I/II study adding ONCOS-102 to
title:    pemetrexed/cisplatin in patients with unresectable malignant pleural
          mesothelioma - 24-month survival data
E-poster  462
number:
Lead      Dr Luis Paz-Ares, Medical Oncology, Hospital Universitario 12
author:   Octubre, Madrid, Spain

***

Poster    Consistent pattern of immune activation induced by oncolytic
title:    adenovirus ONCOS-102 across diverse types of solid tumors
E-poster  368
number:
Lead      Lukasz Kuryk, PhD, Director Clinical Science, Targovax
author:

***

About SITC

The Society for Immunotherapy of Cancer (SITC) Annual Meeting & Pre-Conference
Programs brings together stakeholders across the cancer immunotherapy field to
advance the science, discover breakthroughs and educate the world on cancer
immunotherapy.

As the largest conference solely focused on cancer immunotherapy, the Annual
Meeting & Pre-Conference Programs provides international leaders from academia,
regulatory and government agencies, as well as industry representatives with a
multidisciplinary educational and interactive environment focused on improving
outcomes for all cancer patients.

For further information, please contact:
Oystein Soug, CEO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient's immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying its multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax's
focus is to "activate the patient's immune system to fight cancer", thus
extending and transforming the lives of cancer patients. Targovax's pipeline
aims at different cancer indications, including melanoma, mesothelioma and
colorectal cancer. The company's product candidates are designed to harness the
patient's own immune system to fight the cancer, whilst also delivering a
favorable safety and tolerability profile.

Targovax's lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both in monotherapy and in
multiple combinations, the next development steps for ONCOS-102 will be to
further improve responses in melanoma patients resistant to or poorly responsive
to current standard of care.

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange